The 36-month beta value for ALDX is also noteworthy at 1.37. There are mixed opinions on the stock, with 6 analysts rating it as a “buy,” 2 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for ALDX is 57.82M, and at present, short sellers hold a 6.13% of that float. The average trading volume of ALDX on December 27, 2024 was 464.98K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
ALDX) stock’s latest price update
Aldeyra Therapeutics Inc (NASDAQ: ALDX) has experienced a decline in its stock price by -2.39 compared to its previous closing price of 5.02. However, the company has seen a gain of 0.82% in its stock price over the last five trading days. seekingalpha.com reported 2024-12-26 that Aldeyra Therapeutics is finally nearing commercialization, attracting renewed attention from some analyst firms. Drug giant AbbVie has a significant option agreement on Aldeyra’s primary pipeline asset that will likely be triggered upon FDA approval in April. An updated analysis around Aldeyra Therapeutics follows in the paragraphs below.
ALDX’s Market Performance
Aldeyra Therapeutics Inc (ALDX) has seen a 0.82% rise in stock performance for the week, with a 2.08% gain in the past month and a -10.91% plunge in the past quarter. The volatility ratio for the week is 5.07%, and the volatility levels for the past 30 days are at 6.02% for ALDX. The simple moving average for the past 20 days is -1.87% for ALDX’s stock, with a 8.68% simple moving average for the past 200 days.
Analysts’ Opinion of ALDX
Many brokerage firms have already submitted their reports for ALDX stocks, with Oppenheimer repeating the rating for ALDX by listing it as a “Outperform.” The predicted price for ALDX in the upcoming period, according to Oppenheimer is $10 based on the research report published on April 03, 2024 of the current year 2024.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see ALDX reach a price target of $10. The rating they have provided for ALDX stocks is “Buy” according to the report published on April 02nd, 2024.
H.C. Wainwright gave a rating of “Buy” to ALDX, setting the target price at $15 in the report published on April 27th of the previous year.
ALDX Trading at -3.68% from the 50-Day Moving Average
After a stumble in the market that brought ALDX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -25.16% of loss for the given period.
Volatility was left at 6.02%, however, over the last 30 days, the volatility rate increased by 5.07%, as shares surge +0.20% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -10.97% lower at present.
During the last 5 trading sessions, ALDX rose by +1.85%, which changed the moving average for the period of 200-days by +70.69% in comparison to the 20-day moving average, which settled at $5.00. In addition, Aldeyra Therapeutics Inc saw 39.60% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ALDX starting from Machatha Stephen, who sale 16,041 shares at the price of $4.74 back on Aug 12 ’24. After this action, Machatha Stephen now owns 236,771 shares of Aldeyra Therapeutics Inc, valued at $75,975 using the latest closing price.
Greenberg Bruce sale 10,834 shares at $4.74 during a trade that took place back on Aug 12 ’24, which means that Greenberg Bruce is holding 126,382 shares at $51,313 based on the most recent closing price.
Stock Fundamentals for ALDX
Current profitability levels for the company are sitting at:
- -126.43 for the present operating margin
- 0.52 for the gross margin
The net margin for Aldeyra Therapeutics Inc stands at -114.09. The total capital return value is set at -0.5. Equity return is now at value -43.05, with -33.86 for asset returns.
Based on Aldeyra Therapeutics Inc (ALDX), the company’s capital structure generated 0.15 points at debt to capital in total, while cash flow to debt ratio is standing at -2.01. The debt to equity ratio resting at 0.18. The interest coverage ratio of the stock is -25.2.
Currently, EBITDA for the company is -35.21 million with net debt to EBITDA at 0.29. When we switch over and look at the enterprise to sales, we see a ratio of 717.41. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.64.
Conclusion
In summary, Aldeyra Therapeutics Inc (ALDX) has had a better performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
